Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines

Zorana Jovanovic Andersen, Ulrike Gehring, Sara De Matteis, Erik Melen, Ana Maria Vicedo-Cabrera, Klea Katsouyanni, Arzu Yorgancioglu, Charlotte Suppli Ulrik, Sylvia Medina, Kjeld Hansen, Pippa Powell, Brian Ward, Barbara Hoffmann
European Respiratory Journal 2021 58: 2102447; DOI: 10.1183/13993003.02447-2021
Zorana Jovanovic Andersen
1Dept of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zorana.andersen@sund.ku.dk
Ulrike Gehring
2Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ulrike Gehring
Sara De Matteis
3Dept of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
4Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Melen
5Dept of Clinical Sciences and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erik Melen
Ana Maria Vicedo-Cabrera
6Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
7Oeschger Center for Climate Change Research, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klea Katsouyanni
8National and Kapodistrian University of Athens, Medical School, Athens, Greece
9Environmental Research Group, School of Public Health, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arzu Yorgancioglu
10Medical Faculty, Dept of Pulmonology, Celal Bayar University, Manisa, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Suppli Ulrik
11Dept of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark
12Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charlotte Suppli Ulrik
Sylvia Medina
13Direction of Environmental and Occupational Health, Santé Publique France, Saint Maurice, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kjeld Hansen
14European Lung Foundation, Sheffield, UK
15Kristiania University College, Technology, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pippa Powell
14European Lung Foundation, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Ward
16European Respiratory Society, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Hoffmann
17Institute for Occupational, Social and Environmental Medicine, Centre for Health and Society, Medical Faculty, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Air pollution poses a major burden to respiratory patients and legislation fails to protect them. Urgent action and alignment of air quality standards with WHO guidelines are needed to ensure healthier lungs and tackle the climate change crisis. https://bit.ly/3B04dKB

Aim

This statement outlines how air pollution affects patients with lung disease, highlights the main messages of the 2021 World Health Organization (WHO) Air Quality Guidelines, points out how the ambitious European Union (EU) Green Deal can provide solutions through a modern air quality legislation, and discusses the role of respiratory clinicians in improving air quality-related lung health.

The burden of air pollution is enormous and increasing

Air pollution is a major risk factor to public health globally, contributing to morbidity and mortality from respiratory, cardiovascular and cerebrovascular disease, and lung cancer [1]. Every year, air pollution leads to 509 000 premature deaths in Europe and serious aggravations of lung and heart diseases that affect millions of children and adults [2]. Because of the links with multiple diseases and the ubiquitous nature of the exposure, air pollution is the fourth leading risk factor for morbidity and mortality in the 2019 Global Burden of Disease study, surpassed only by high blood pressure, tobacco use and poor diet [3]. Moreover, as we are learning more about the effects of air pollution on health outcomes, such as diabetes, neurodegenerative diseases, neonatal deaths, cancers other than lung cancer, etc., our estimates of disease burden caused by air pollution are still rising [3].

Respiratory patients are susceptible to adverse effects of air pollution

Respiratory disease patients, both children and adults, are arguably the most susceptible to the effects of air pollution. The respiratory tract is the first portal of entry for air pollutants and consequently the effects of air pollution on the respiratory system have been studied most intensively for decades [4, 5]. Air pollution affects lungs, starting in pregnancy and continuing throughout the entire lifetime. Typical biological effects of air pollution include a suppressed immune system [6–9], inflammation and oxidative stress effects, impaired lung growth in children [10, 11], lung function decrements in children and adults, and carcinogenic effects [12, 13]. Thereby, long-term exposure to air pollution in healthy people increases risk of development of new respiratory diseases, such as asthma in children [14] and adults [15], COPD [16], acute lower respiratory infections [17], and lung cancer [17, 18], and it increases the risk of premature death due to respiratory or cardiovascular disease [19]. Furthermore, air pollution presents a substantial burden in the daily life of respiratory disease patients, where exposure to short-term peaks in air pollution can trigger exacerbations of manifest disease, such as asthma attacks, increased use of reliever medication, emergency room visits, hospitalisations, and even death [4, 5]. Finally, people with respiratory disease are more susceptible to development of other diseases that have been linked to air pollution, such as cardiovascular diseases, diabetes, neurodegenerative diseases, etc. [1].

Most recently, emerging evidence is also showing that air pollution likely contributes to the risk of hospitalisation and death from coronavirus disease 2019 (COVID-19) [20, 21]. Of note, the current COVID-19 pandemic has added another group of potentially susceptible patients, including not only COVID-19 cases, but also patients with “long-COVID”, denoting COVID-19 survivors with one or more disease signs/symptoms (e.g. an impaired lung function, decreased diffusing capacity of the lung for carbon monoxide, and persistent dyspnoea) ≥12 weeks after recovery, where air pollution-related inflammation may play a role in disease prognosis [22].

As everyone is exposed to varying levels of air pollution, and prevalence of potentially impacted health outcomes is high, the burden of air pollution on respiratory diseases is huge. The traffic-related air pollutant nitrogen dioxide (NO2) has been estimated to be associated with 4 million or 13% of all new asthma cases in children, globally, every year [23]. Similarly, 40% of COPD deaths, 30% of acute lower respiratory tract infection deaths, and 19% of all lung cancer deaths globally have been estimated to be attributable to total air pollution [1]. A recent coroner's ruling in a landmark case in London, UK, acknowledging air pollution as a primary cause in the death of Ella Kissi-Debrah, a 6-year-old severe asthma patient, has major significance in recognising the severe health consequences of air pollution. The ruling stated that Ella's death in February 2013 was caused by acute respiratory failure, severe asthma, and air pollution exposure to traffic-related NO2 and particulate matter (PM) pollution around her home, which exceeded the WHO guidelines [24]. The ruling also stated that the failure to reduce pollution levels to legal limits, as well as the failure to provide her mother with information about the potential for air pollution to exacerbate asthma, possibly contributed to Ella's death. This is the first ruling of its kind globally, that has referred to air pollution as a public health emergency. It will likely play a role in increasing pressure on governments to tackle unlawful levels of air pollution, as well as on respiratory clinicians to better inform their patients on harms related to air pollution.

EU air quality legislation and WHO air quality guidelines

EU policy on air quality includes ambient air quality directives that set air quality standards to provide protection from excessive pollution concentrations in the entire EU and thereby protect the health of European citizens. The EU's Ambient Air Quality Directives (AAQD) (2008/50/EC Directive on Ambient Air Quality and Cleaner Air for Europe and 2004/107/EC Directive on heavy metals and polycyclic aromatic hydrocarbons in ambient air) set legally binding pollutant concentration thresholds, so-called limit values, that shall not be exceeded in a given period of time (table 1). For the assessment of the health-related scientific basis, the EU relies on the WHO and its Air Quality Guidelines on outdoor air pollution. However, while the 2005 WHO guidelines already recommended that annual average concentrations of PM2.5 should not exceed 10 µg·m−3 and annual average concentration for NO2 should not exceed 40 µg·m−3, the currently still effective limit values of 2008 were set at 25 µg·m−3 and 40 µg·m−3, respectively. Therefore, while following the 2005 WHO recommendations for NO2, the high limit value for PM2.5 already refutes the EU's overarching aim of comprehensive protection.

View this table:
  • View inline
  • View popup
TABLE 1

Comparison of limit values set by the 2008 European Union (EU) Ambient Air Quality Directive and World Health Organization (WHO) Air Quality Guidelines 2005 and 2021 for several major pollutants

In September 2021, the WHO updated its 2005 recommendations, providing a comprehensive synthesis of the research on the health effects of air pollution, including extensive amounts of high-quality evidence that has been published during the past 15 years [25]. The new WHO 2021 Air Quality Guidelines make a historic, bold statement, by setting strikingly lower recommendations than those set in 2005, with greatest changes for annual average concentrations of PM2.5 set at 5 µg·m−3 and for NO2 set at 10 µg·m−3 (table 1). The new guidelines also highlight the linear exposure–response relationship of air pollution with mortality and other major health effects, down to the lowest observable concentrations. Most importantly, this implies that any improvements in air quality will result in health benefits, even at concentrations well below current or future limit values [19]. The new guidelines also point to increasing evidence for adverse health effects of air pollution well and far beyond those on the cardio-respiratory system, acknowledging new associations with diabetes, neonatal deaths, and increasing research on cognitive development, neurodegenerative diseases, cancers other than lung cancer, and even psychological disorders. The main messages of the updated WHO Air Quality Guidelines are clear and alarming: there are no levels of air pollution below which air pollution is safe for human health.

How do we move forward?

The European Commission adopted the European Green Deal (EGD) in December 2019 as a strategy to be the first climate neutral continent in the world. An integral part of the EGD is a “Zero Pollution Ambition”, at the core of which is clean air. Within the EGD, the European Commission proposed in 2019 to revise its air quality standards and committed to align them more closely with the WHO Air Quality Guidelines. Now, even more so than before, the new guidelines clearly expose the large gap between evidence-based recommendations for air quality and current EU limit values for major pollutants.

While many EU member states today comply with most of the current legally binding fixed limit values, the new guidelines clearly show that this is not enough to protect the health of EU citizens. The new WHO guidelines provide the comprehensive evidence on health effects at levels well below current limit values that is needed to fundamentally revise our thinking about air quality regulation. So far, most air quality legislations, such as the EU AAQD, have adopted fixed limit values, which offer little benefit to those citizens already living at concentrations below these limit values. For a more efficient protection of health, an incremental reduction of the exposure of the entire population is crucial. The European Commission already recognised this in 2008 and included a so-called average exposure indicator for PM2.5 in its 2008 AAQD. However, no binding targets for reduction were set, rendering this potentially very effective instrument a “toothless tiger”. For an efficient and effective prevention of air pollution-related diseases, a combination of legally enforceable fixed limit values and legally enforceable reductions of average population exposure is mandatory. An example of enforcement measures could be EU financial penalties on member countries not preparing and following through on implementation plans to meet the air quality standards.

The guidelines were delivered just in time for legislative action and for a fundamental revision of air quality policy in the EU. The time to act and deliver an ambitious air quality legislation in Europe as an example for actions around the globe is now. The guidelines serve as a wake-up call to act now to call for and implement bold policies and structural changes in our cities, transportation, industry, agriculture and energy systems, to ensure long-term reductions in air pollution. Cleaner air will provide immediate health benefits to all European citizens, ensure healthier lungs, prevent a substantial number of new respiratory diseases, and provide for a better life of patients with lung diseases. Furthermore, clean air policies have important co-benefits in tackling the unprecedented and irreversible climate change crises [26] we are facing, making them central to ensuring a healthier and more resilient environment, planet and populations. Healthcare professionals need to play a central role in informing and advising patients about the harms related to air pollution and together with their patients, present an important voice demanding cleaner air for healthier lungs.

What can respiratory clinicians do?

The role of clinicians is a key one, both for prevention and management of respiratory health effects associated with air pollution exposure. They are the “first line” source of scientifically reliable information for patients who are often overwhelmed, and sometimes misinformed, by the plethora of opinions provided on social media, and crave for clear advice from real experts. Moreover, healthcare professionals are the prime advocates of their patients for clean air policies and should raise their voices for effective prevention and protection from environment-related harm.

To be able to fulfil this role, we recommend:

  • Inclusion of environment-related health issues in the core medical training of future healthcare professionals

  • Inclusion of environment-related health issues in continuing medical education courses, provided, for example, by medical societies

  • Clinicians always to ask their patients about environmental exposures, in addition to questions about active and second-hand tobacco smoking

  • Development of evidence-based clinical guidelines for treatment and prevention of environment-related disease

  • Advocating for appropriate reimbursement policies by health insurance for guideline-recommended personal protection devices

  • Engagement with patient representatives for awareness raising, educating and advising patients, specifically the most susceptible and vulnerable patient groups

  • Raising their voices for clean air policies as advocates of their patients’ health

Who we are

The European Respiratory Society (ERS) is an international organisation that brings together physicians, other healthcare professionals, epidemiologists, patient representatives, scientists and other experts working in respiratory medicine. We are one of the leading medical organisations in the respiratory field, with a growing membership representing over 160 countries. Our mission is to promote lung health and alleviate suffering from disease, and drive standards for prevention of respiratory diseases as well as respiratory medicine globally. Science, education and advocacy are at the core of everything we do. This position was developed and led by the ERS Environment and Health Committee and the European Lung Foundation.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02447-2021.Shareable

Footnotes

  • Conflict of interest: Z.J. Andersen reports participation on the WHO GAPH Technical Advisory Group, holds an unpaid role with the European Respiratory Society, outside the submitted work.

  • Conflict of interest: U. Gehring has nothing to disclose.

  • Conflict of interest: S. De Matteis has nothing to disclose.

  • Conflict of interest: E. Melén is a member of the ERS Environmental Health Committee.

  • Conflict of interest: A.M. Vicedo-Cabrera has nothing to disclose.

  • Conflict of interest: K. Katsouyanni reports research grants from the EC (Horizon2020) and the US Health Effects Institute, outside the submitted work, and is a member of the WHO GAPH Technical Advisory Group.

  • Conflict of interest: A. Yorgancioglu is the Advocacy Council Chair of ERS and receives support for travel and accommodation at ERS meetings.

  • Conflict of interest: C.S. Ulrik reports fees for lectures from AZ, GSK, TEVA, Sanofi, Orion Pharma, Novartis and Chiesi, outside the submitted work.

  • Conflict of interest: S. Medina is an employee of Santé publique France.

  • Conflict of interest: K. Hansen is part of the leadership of the European Lung Foundation and the European Respiratory Society.

  • Conflict of interest: P. Powell is an employee of ELF.

  • Conflict of interest: B. Ward is an employee of ERS.

  • Conflict of interest: B. Hoffmann is a member of the research committee for Health Effects Institute, Boston, USA.

  • Received September 13, 2021.
  • Accepted September 22, 2021.
  • Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. The Health Effects Institute (HEI)
    . State of Global Air 2020. Special Report. www.stateofglobalair.org/
  2. ↵
    1. European Environment Agency (EEA)
    . Air Quality in Europe - 2020 Report. EEA Report. Luxembourg, European Union, 2020.
  3. ↵
    1. Abbafati C,
    2. Machado DB,
    3. Cislaghi B, et al.
    Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223–1249. doi:10.1016/S0140-6736(20)30752-2
    OpenUrlCrossRefPubMed
  4. ↵
    1. Schraufnagel DE,
    2. Balmes JR,
    3. Cowl CT, et al.
    Air pollution and noncommunicable diseases: a review by the Forum of International Respiratory Societies’ Environmental Committee, Part 1: the damaging effects of air pollution. Chest 2019; 155:409–416. doi:10.1016/j.chest.2018.10.042
    OpenUrlCrossRefPubMed
  5. ↵
    1. Schraufnagel DE,
    2. Balmes JR,
    3. Cowl CT, et al.
    Air pollution and noncommunicable diseases: a review by the Forum of International Respiratory Societies’ Environmental Committee, Part 2: air pollution and organ systems. Chest 2019; 155: 417–426. doi:10.1016/j.chest.2018.10.041
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ciencewicki J,
    2. Jaspers I
    . Air pollution and respiratory viral infection. Inhal Toxicol 2007; 19: 1135–1146. doi:10.1080/08958370701665434
    OpenUrlCrossRefPubMedWeb of Science
    1. Pompilio A,
    2. Di Bonaventura G
    . Ambient air pollution and respiratory bacterial infections, a troubling association: epidemiology, underlying mechanisms, and future challenges. Crit Rev Microbiol 2020; 46: 600–630. doi:10.1080/1040841X.2020.1816894
    OpenUrl
    1. Mehta S,
    2. Shin H,
    3. Burnett R, et al.
    Ambient particulate air pollution and acute lower respiratory infections: a systematic review and implications for estimating the global burden of disease. Air Qual Atmos Health 2013; 6: 69–83. doi:10.1007/s11869-011-0146-3
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Brugha R,
    2. Grigg J
    . Urban air pollution and respiratory infections. Paediatr Respir Rev 2014; 15: 194–199.
    OpenUrlPubMed
  8. ↵
    1. Schultz ES,
    2. Hallberg J,
    3. Bellander T, et al.
    Early-life exposure to traffic-related air pollution and lung function in adolescence. Am J Respir Crit Care Med 2016; 193: 171–177. doi:10.1164/rccm.201505-0928OC
    OpenUrlCrossRefPubMed
  9. ↵
    1. Schultz ES,
    2. Litonjua AA,
    3. Melén E
    . Effects of long-term exposure to traffic-related air pollution on lung function in children. Curr Allergy Asthma Rep 2017; 17: 41. doi:10.1007/s11882-017-0709-y
    OpenUrlPubMed
  10. ↵
    1. Adam M,
    2. Schikowski T,
    3. Carsin AE, et al.
    Adult lung function and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis. Eur Respir J 2015; 45: 38–50. doi:10.1183/09031936.00130014
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Doiron D,
    2. de Hoogh K,
    3. Probst-Hensch N, et al.
    Air pollution, lung function and COPD: results from the population-based UK Biobank study. Eur Respir J 2019; 54: 1802140. doi:10.1183/13993003.02140-2018
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Khreis H,
    2. Kelly C,
    3. Tate J, et al.
    Exposure to traffic-related air pollution and risk of development of childhood asthma: a systematic review and meta-analysis. Environ Int 2017; 100: 1–31. doi:10.1016/j.envint.2016.11.012
    OpenUrlPubMed
  13. ↵
    1. Liu S,
    2. Jørgensen JT,
    3. Ljungman P, et al.
    Long-term exposure to low-level air pollution and incidence of asthma: the ELAPSE project. Eur Respir J 2021; 57: 2003099. doi:10.1183/13993003.030992020
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Liu S,
    2. Jørgensen JT,
    3. Ljungman P, et al.
    Long-term exposure to low-level air pollution and incidence of chronic obstructive pulmonary disease: The ELAPSE project. Environ Int 2021; 146: 106267. doi:10.1016/j.envint.2020.106267
    OpenUrl
  15. ↵
    1. Grigg J
    . Air pollution and respiratory infection: an emerging and troubling association. Am J Respir Crit Care Med 2018: 198: 700–701. doi:10.1164/rccm.201804-0614ED
    OpenUrlPubMed
  16. ↵
    1. Raaschou-Nielsen O,
    2. Andersen ZJ,
    3. Beelen R, et al.
    Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013; 14: 813–822. doi:10.1016/S1470-2045(13)70279-1
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Chen J,
    2. Hoek G
    . Long-term exposure to PM and all-cause and cause-specific mortality: a systematic review and meta-analysis. Environ Int 2020; 143: 105974. doi:10.1016/j.envint.2020.105974
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bowe B,
    2. Xie Y,
    3. Gibson AK, et al.
    Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: cohort study. Environ Int 2021; 154: 106564. doi:10.1016/j.envint.2021.106564
    OpenUrlPubMed
  19. ↵
    1. Brunekreef B,
    2. Downward GS,
    3. Forastiere F, et al.
    Air pollution and COVID-19. Including elements of air pollution in rural areas, indoor air pollution and vulnerability and resilience aspects of our society against respiratory disease, social inequality stemming from air pollution. Study for the committee on Environment, Public Health and Food Safety, Policy Department for Economic, Scientific and Quality of Life Policies. Luxembourg, European Union, 2021.
  20. ↵
    1. Qin W,
    2. Chen S,
    3. Zhang Y, et al.
    Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up. Eur Respir J 2021; 58: 2003677. doi:10.1183/13993003.03677-2020
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Achakulwisut P,
    2. Brauer M,
    3. Hystad P, et al.
    Global, national, and urban burdens of paediatric asthma incidence attributable to ambient NO2 pollution: estimates from global datasets. Lancet Planet Health 2019; 3: e166–e178. doi:10.1016/S2542-5196(19)30046-4
    OpenUrlPubMed
  22. ↵
    1. World Health Organization
    . Air Quality Guidelines. Global Update 2005. Copenhagen, World Health Organization, 2006.
  23. ↵
    1. World Health Organization
    . WHO Global Air Quality Guidelines: Particulate Matter (PM2.5 and PM10) , Ozone, Nitrogen Dioxide, Sulfur Dioxide and Carbon Monoxide. Geneva, World Health Organization, 2021.
  24. ↵
    1. IPCC
    . 2021: Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change. In: Masson-Delmotte V, Zhai P, Pirani A, et al., eds. Cambridge, Cambridge University Press; in press.
Next
Back to top
View this article with LENS
Vol 58 Issue 6 Table of Contents
European Respiratory Journal: 58 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines
Zorana Jovanovic Andersen, Ulrike Gehring, Sara De Matteis, Erik Melen, Ana Maria Vicedo-Cabrera, Klea Katsouyanni, Arzu Yorgancioglu, Charlotte Suppli Ulrik, Sylvia Medina, Kjeld Hansen, Pippa Powell, Brian Ward, Barbara Hoffmann
European Respiratory Journal Dec 2021, 58 (6) 2102447; DOI: 10.1183/13993003.02447-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines
Zorana Jovanovic Andersen, Ulrike Gehring, Sara De Matteis, Erik Melen, Ana Maria Vicedo-Cabrera, Klea Katsouyanni, Arzu Yorgancioglu, Charlotte Suppli Ulrik, Sylvia Medina, Kjeld Hansen, Pippa Powell, Brian Ward, Barbara Hoffmann
European Respiratory Journal Dec 2021, 58 (6) 2102447; DOI: 10.1183/13993003.02447-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Aim
    • The burden of air pollution is enormous and increasing
    • Respiratory patients are susceptible to adverse effects of air pollution
    • EU air quality legislation and WHO air quality guidelines
    • How do we move forward?
    • What can respiratory clinicians do?
    • Who we are
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Nintedanib in chILD: a small step
  • GM-CSF targeting in COVID-19
  • EBAP: reflections on 20 years of CME in respiratory medicine
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society